What do my esophagogastroduodenoscopy (EGD) results indicate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Understanding Your EGD Results

Your esophagogastroduodenoscopy (EGD) results should be interpreted based on why the test was performed and what specific findings were documented. The clinical significance depends entirely on your symptoms, risk factors, and the endoscopic and histologic findings.

Key Clinical Contexts for EGD Interpretation

If You Had Alarm Symptoms

EGD is definitively indicated when you have dysphagia, bleeding, anemia, weight loss, or recurrent vomiting 1. These symptoms warrant endoscopy because they have high yield for clinically actionable findings like esophageal or gastric cancer, bleeding lesions, or strictures. If your EGD was performed for these reasons, the findings directly address whether serious pathology is present.

If You Had GERD Symptoms Despite Treatment

EGD is indicated only after 4-8 weeks of twice-daily proton pump inhibitor (PPI) therapy has failed to control typical GERD symptoms 1. If you underwent EGD for persistent heartburn or regurgitation despite adequate PPI treatment, the results determine whether complications like severe erosive esophagitis, Barrett's esophagus, or strictures are present.

  • For severe erosive esophagitis (grade B or worse): A follow-up EGD after 8 weeks of PPI therapy is recommended to ensure healing and rule out Barrett's esophagus 1. If that follow-up is normal, no further routine endoscopy is needed.
  • For Barrett's esophagus without dysplasia: Surveillance EGD should occur at 3-5 year intervals 1. More frequent surveillance is needed if dysplasia is found.
  • For esophageal stricture: Repeat EGD with dilation may be required if dysphagia symptoms recur 1.

If You Had Screening for Barrett's Esophagus or Cancer

Routine screening EGD should not be performed in women of any age or men under 50 years, regardless of GERD symptoms, due to very low cancer incidence 1.

Screening may be considered in men over 50 years with chronic GERD (>5 years) plus additional risk factors including nocturnal reflux, hiatal hernia, elevated BMI, tobacco use, and central obesity 1. This decision must account for life-limiting comorbidities. If the initial screening is negative, repeat endoscopy is not indicated.

If You Had Dysphagia Without Endoscopic Explanation

When EGD is performed for dysphagia but shows no findings to explain it, high-resolution esophageal manometry should be the next step 2, 3. Incidental findings like hiatal hernia, tortuous esophagus, or Barrett's esophagus do not explain dysphagia and should not prevent manometry referral 3. Approximately 30-50% of such patients have esophageal motility disorders detectable only by manometry.

Critical Pitfalls to Avoid

Do not assume normal EGD excludes significant disease if you have persistent dysphagia - manometry is essential 3, 4. Endoscopists may incorrectly attribute dysphagia to incidental findings, leading to underutilization of appropriate testing.

Do not undergo repeat surveillance EGD without clear indication - if you had severe esophagitis that healed without Barrett's esophagus, or if you're being screened without meeting high-risk criteria, repeat endoscopy adds cost and risk without benefit 1.

Biopsies matter significantly - if your EGD report mentions biopsies were taken, ensure you receive and act on histology results 5. Management recommendations often depend on pathology (H. pylori status, presence of intestinal metaplasia, dysplasia grade).

What Your Results Should Include

A complete EGD report should document 6, 5:

  • Photo documentation of anatomical landmarks and any lesions
  • Quality of mucosal visualization
  • Standardized classification of findings (Prague classification for Barrett's, Paris classification for lesions)
  • Biopsy locations and rationale
  • Management recommendations based on findings
  • Whether surveillance is indicated and at what interval

If your report lacks these elements or if management recommendations are unclear, request clarification from your endoscopist 5.

Related Questions

What is the ICD-10 code for esophageal atresia?
In a patient with suspected esophageal cancer, should a barium swallow study or an esophagogastroduodenoscopy (EGD) be performed first?
In a 48-year-old patient with Barrett's esophagus (intestinal-type epithelium at the gastroesophageal junction), what cancer is the patient at significantly increased risk of developing?
What is the next step in evaluating and managing a patient with persistent nausea after a normal esophagogastroduodenoscopy (EGD) and normal wireless pH‑impedance (Bravo) study?
What should I expect when preparing for an esophagogastroduodenoscopy (EGD)?
What are the clinical phenotype and presentation of a patient with a large 22q deletion encompassing the FGFR3 gene?
What is the pharmacological management algorithm for atrial fibrillation in a patient with inadequate rate control (ventricular rate >80 bpm at rest or >110 bpm with activity) despite maximally tolerated beta‑blocker or non‑dihydropyridine calcium‑channel blocker?
What is the minimal clinically important difference (MCID) for exercise-based pulmonary rehabilitation in idiopathic pulmonary fibrosis, specifically regarding the six‑minute walk distance?
Before administering magnesium sulfate, which baseline laboratory and clinical assessments should be obtained to prevent toxicity?
What are the clinical manifestations and management of magnesium sulfate toxicity?
What are the recommended treatment options for osteopenia, including calcium and vitamin D supplementation, lifestyle measures, and pharmacotherapy such as bisphosphonates or denosumab?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.